Recent News

• 02.11.2026 - iMDx Announces $26.0 Million Registered Direct Offering
• 01.13.2026 - IMDX Supports AST and ASHI STAR Working Group’s Call for Decentralized Transplant Monitoring
• 01.07.2026 - iMDx Announces “JPM Week” and “BTIG Snowbird” Conference Participation
• 01.06.2026 - iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay Launch
• 01.05.2026 - iMDx Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears Completion
• 11.10.2025 - IMDX Reports Q3 2025 Results and Progress Toward 2026 Commercial Launch
• 11.03.2025 - iMDx to Release Third Quarter 2025 Results on November 10 and Attend Stephens Annual Investment Conference the Following Week
• 10.13.2025 - iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay Launch
• 10.06.2025 - iMDx Reports Kidney Transplant Patient Achieved ‘Immune Reset’ with Novel Therapy and GraftAssure Monitoring

Recent Filings

• 02.11.2026 - 8-K Current report
• 02.11.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 02.11.2026 - EX-99.1 EX-99.1
• 11.13.2025 - 4/A Statement of changes in beneficial ownership of securities
• 11.10.2025 - EX-99.1 EX-99.1
• 11.10.2025 - 8-K Current report
• 11.10.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.02.2025 - 8-K Current report
• 09.30.2025 - 4 Statement of changes in beneficial ownership of securities